Oncology

PET Imaging Reveals Which Breast Cancer Patients Won’t Respond to Hormone Therapy

02/14/2021

Excerpt from the Article: Hormone therapy is only effective in roughly half of estrogen receptor-positive cancers. Being able to identify patients that will not respond could save valuable treatment time. The answer to whether hormone replacement therapy will work for a woman with breast cancer likely comes down to whether her estrogen receptors are working…

Read More

Using MRI for prostate cancer diagnosis equals or beats current standard

02/08/2021

Excerpt from the Press Release: Toronto – (February 4, 2021) The results of a Phase III randomized clinical trial have shown that when it comes to detecting clinically significant prostate cancer, Magnetic Resonance Imaging (MRI) with targeted biopsies (MRI-TBx) matches the current standard and brings a multitude of advantages. The PRostate Evaluation for Clinically Important…

Read More

Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer

02/03/2021

Excerpt from the Press Release: REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the first patient dosed in the Phase 2 TENACITY clinical trial of…

Read More

NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer

02/02/2021

Excerpt from the Press Release: “We believe that NBTXR3 could have a positive impact for patients with cancer in any case where radiotherapy is a part of the standard of care. Expansion into esophageal cancer represents not only another step toward achieving our goals, it also highlights the ongoing progress of our clinical collaboration agreement…

Read More

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

01/12/2021

Excerpt from the Press Release: DURHAM, NC, USA I January 8, 2021 I Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead…

Read More

Study points the way to boost immunotherapy against breast cancer, other solid tumors

01/04/2021

Excerpt from the Article: Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center. The boost helps recruit more…

Read More

Triple chemotherapy combination improves metastatic colorectal cancer outcomes

12/31/2020

Excerpt from the Press Release: Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination – of irinotecan, cetuximab, and vemurafenib – is a more powerful tumor fighter and keeps people with metastatic…

Read More

Global trial reveals life saving drug for acute myeloid leukemia

12/30/2020

Excerpt from the Article: A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML).  The Phase 3 clinical trial called QUAZAR, showed that a drug,…

Read More

PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment of Metastatic Solid Tumors

12/18/2020

Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the initiation of its Phase 1 clinical trial of LYT-200 for the potential treatment of metastatic solid tumors that are…

Read More

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

12/17/2020

Excerpt from the Press Release: SAN DIEGO, Dec. 10, 2020 /PRNewswire/ — Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, provided a clinical update on their lead program ARX788, a homogeneous and highly stable, site-specific antibody drug conjugate (ADC) targeting HER2 positive cancers. “As presented at the 2020…

Read More